Catalyst Pharmaceuticals, Inc

(NASDAQ:CPRX)

Latest On Catalyst Pharmaceuticals, Inc (CPRX):

Date/Time Type Description Signal Details
2023-05-11 18:16 ESTNewsCatalyst Pharmaceuticals (CPRX) Q1 2023 Earnings Call TranscriptN/A
2023-05-11 03:27 ESTNewsCatalyst Pharmaceuticals beats Q1 top and bottom line estimates; reaffirms FY23 outlookN/A
2023-05-10 01:27 ESTNewsCatalyst Pharmaceuticals Q1 2023 Earnings PreviewN/A
2023-04-19 09:17 ESTNewsCatalyst Pharmaceuticals: Fixing Its Misnomer Is No Easy TaskN/A
2023-04-18 21:51 ESTNewsCatalyst Pharma And Teva's ANDA Challenge: Firdapse Hangs By A ThreadN/A
2023-04-17 20:10 ESTNewsCatalyst Pharmaceuticals: A One-Hit Wonder With UpsideN/A
2023-03-31 18:52 ESTNewsDefense Is The Best Offense: 3 Stocks To BuyN/A
2023-03-16 16:11 ESTNewsCatalyst Pharmaceuticals, Inc. (CPRX) Q4 2022 Earnings Call TranscriptN/A
2023-03-16 01:07 ESTNewsCatalyst Pharmaceuticals Non-GAAP EPS of $0.31 beats by $0.11, revenue of $60.76M beats by $0.12MN/A
2023-03-14 18:44 ESTNewsCatalyst Pharmaceuticals Q4 2022 Earnings PreviewN/A
2023-02-07 17:49 ESTNewsCatalyst Pharmaceuticals jumps 2% on prelim Q4 and FY 2022 reportsN/A
2023-02-01 02:51 ESTNewsCatalyst Pharmaceuticals: Stable Upside Potential Amid Patent Infringement ConcernsN/A
2023-01-31 14:06 ESTNewsCatalyst Pharmaceuticals: Teva's Patent Challenge Of Firdapse Could Spell The End For This Cash CowN/A
2023-01-31 01:26 ESTNewsCatalyst Pharmaceuticals: The Firdapse Complexity Does Not EndN/A
2023-01-23 13:52 ESTNewsCatalyst stock slumps ~20% as Teva seeks FDA approval of generic FirdapseN/A
2022-12-20 09:43 ESTNewsCatalyst Pharma gains U.S. rights to Eisai epilepsy drug FycompaN/A
2022-11-22 18:17 ESTNewsCatalyst Pharma hits 52-week high amid acquisition hopesN/A
2022-11-15 17:12 ESTNewsCatalyst Pharmaceuticals: Undervalued And Likely To OutperformN/A
2022-11-10 15:03 ESTNewsCatalyst Pharmaceuticals, Inc. (CPRX) Q3 2022 Earnings Call TranscriptN/A
2022-11-09 22:21 ESTNewsCatalyst Pharmaceuticals Non-GAAP EPS of $0.26 beats by $0.07, revenue of $57.24M beats by $3.55MN/A
2022-11-09 04:06 ESTNewsCatalyst Pharmaceuticals Q3 2022 Earnings PreviewN/A
2022-09-17 01:33 ESTNewsCatalyst Pharma falls after a series of insider salesN/A
2022-09-14 20:33 ESTNewsCatalyst Pharmaceuticals Ramp May Be Over For NowN/A
2022-09-13 08:44 ESTNewsCatalyst Pharmaceuticals gains 9% on SmallCap 600 additionN/A
2022-09-13 08:44 ESTNewsHot Stocks: ORCL gains on earnings, WKHS jumps on patent, CPRX rises, TSN dips on downgradeN/A
2022-08-24 18:50 ESTNewsCatalyst Pharma ends momentum as Roth downgradesN/A
2022-08-12 17:09 ESTNewsCatalyst Pharmaceuticals: Performing Above ExpectationsN/A
2022-08-10 14:35 ESTNewsCatalyst stock rises 20% as Firdapse revenue grows with Ruzurgi woes settledN/A
2022-08-10 14:35 ESTNewsCatalyst Pharmaceuticals, Inc. (CPRX) CEO Patrick McEnany on Q2 2022 Results - Earnings Call TranscriptN/A
2022-08-09 21:44 ESTNewsCatalyst Pharmaceuticals Non-GAAP EPS of $0.28 beats by $0.11, revenue of $53.11M beats by $4.03M, re-affirms FY22 guidanceN/A
2022-08-09 00:34 ESTNewsCatalyst Pharmaceuticals Q2 2022 Earnings PreviewN/A
2022-07-12 08:00 ESTNewsCatalyst settles patent lawsuit for autoimmune disorder drug Firdapse with JacobusN/A
2022-05-27 02:25 ESTNewsCatalyst Pharmaceuticals (CPRX) Investor Presentation - SlideshowN/A
2022-05-13 09:02 ESTNewsCatalyst Pharmaceuticals, Inc.'s (CPRX) CEO Patrick McEnany on Q1 2022 Results - Earnings Call TranscriptN/A
2022-05-11 21:27 ESTNewsCatalyst Pharmaceuticals, Inc. (CPRX) CEO Patrick McEnany on Q1 2022 Results - Earnings Call TranscriptN/A
2022-05-11 21:27 ESTNewsCatalyst Pharmaceuticals Q1 earnings rise Y/Y; reaffirms FY22 revenue outlookN/A
2022-05-11 02:00 ESTNewsCatalyst Pharmaceuticals Non-GAAP EPS of $0.18, revenue of $43.09MN/A
2022-05-11 02:00 ESTNewsCatalyst: Upside Outlier - In Search Of A CatalystN/A
2022-05-10 04:06 ESTNewsCatalyst Pharmaceuticals Q1 2022 Earnings PreviewN/A
2022-03-20 01:07 ESTNewsCatalyst Pharmaceuticals, Inc.'s (CPRX) CEO Patrick McEnany on Q4 2021 Results - Earnings Call TranscriptN/A
2022-03-18 15:46 ESTNewsCatalyst Pharmaceuticals, Inc. (CPRX) CEO Patrick McEnany on Q4 2021 Results - Earnings Call TranscriptN/A
2022-03-17 05:23 ESTNewsCatalyst Pharmaceuticals GAAP EPS of $0.09 misses by $0.03, revenue of $38.31M beats by $0.13MN/A
2022-03-17 05:23 ESTNewsCatalyst Pharmaceuticals' quarterly net gain narrows though revenue increasesN/A
2022-03-15 20:17 ESTNewsCatalyst Pharmaceuticals Q4 2021 Earnings PreviewN/A
2022-03-02 15:22 ESTNewsCatalyst to get 3 more US patents for rare autoimmune disorder drug FirdapseN/A
2022-02-07 19:57 ESTNewsCatalyst Pharmaceuticals expects Q4 revenues to rise 24% Y/Y; provides 2022 outlookN/A
2022-02-04 02:27 ESTNewsCatalyst gets court's favorable judgement in FDA lawsuit over rival drug approvalN/A
2022-01-28 22:32 ESTNewsCatalyst says appeals court issued mandate in its favor in FDA lawsuitN/A
2022-01-20 17:43 ESTNewsCatalyst: A Classic Case Of Watch That BasketN/A
2021-11-15 22:59 ESTNewsCatalyst Pharmaceuticals, Inc.'s (CPRX) CEO Patrick McEnany on Q3 2021 Results - Earnings Call TranscriptN/A

About Catalyst Pharmaceuticals, Inc (CPRX):

Catalyst Pharmaceuticals, Inc., a biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, a proprietary form of amifampridine phosphate for the treatment of patients with lambert-eaton myasthenic syndrome. The company also develops Firdapse, which is in various clinical trials for the treatment of patients with congenital myasthenic syndrome, anti-MuSK antibody positive myasthenia gravis, and spinal muscular atrophy type 3. Catalyst Pharmaceuticals, Inc. has license agreements with BioMarin Pharmaceutical Inc.; and collaboration and license agreement with Endo Ventures Limited for the development and commercialization of generic Sabril tablets. The company was formerly known as Catalyst Pharmaceutical Partners, Inc. and changed its name to Catalyst Pharmaceuticals, Inc. in May 2015. Catalyst Pharmaceuticals, Inc. was founded in 2002 and is based in Coral Gables, Florida.

CPRX Quotes by TradingView

See Advanced Chart

General

  • Name Catalyst Pharmaceuticals, Inc
  • Symbol CPRX
  • Type Common Stock
  • Exchange NASDAQ
  • Currency USD
  • Country USA
  • SectorHealthcare
  • IndustryBiotechnology
  • Full Time Employees 74
  • Fiscal Year EndDecember
  • IPO Date2006-11-08
  • Gic SectorHealth Care
  • Gic GroupPharmaceuticals, Biotechnology & Life Sciences
  • Gic IndustryBiotechnology
  • Gic SubIndustryBiotechnology
  • Web URLhttp://www.catalystpharma.com
View More

Valuation

  • Trailing PE 5.93
  • Forward PE 12.25
  • Price/Sales (Trailing 12 Mt.) 3.77
  • Price/Book (Most Recent Quarter) 2.59
  • Enterprise Value Revenue 2.51
  • Enterprise Value EBITDA 7.08
View More

Financials

  • Most Recent Quarter 2020-12-31
  • Current Year EPS Estimate $0.36
  • Next Year EPS Estimate $0.46
  • Next Quarter EPS Estimate $0.08
  • Profit Margin 63%
  • Operating Margin 35%
  • Return on Assets 17%
  • Return on Equity 58%
  • Revenue 119.07 million
  • Earnings Per Share $0.71
  • Revenue Per Share $1.15
  • Gross Profit 87.12 million
  • Quarterly Earnings Growth 3%
View More

Highlights

  • Market Capitalization 437.1 million
  • EBITDA 41.4 million
  • PE Ratio 25
  • Analyst Target Price $7.5
  • Book Value Per Share $1.63
View More

Share Statistics

  • Shares Outstanding 103.83 million
  • Shares Float 86.56 million
  • % Held by Insiders 698%
  • % Held by Institutions 69.58%
  • Shares Short 8.4 million
  • Shares Short Prior Month 9.21 million
  • Short Ratio 4.4
  • Short % of Float 9%
  • Short % of Shares Outstanding 8%
View More

Technicals

  • Beta 1.35
  • 52 Week High $5.19
  • 52 Week Low $2.88
  • 50 Day Moving Average 4.04
  • 200 Day Moving Average 3.53
View More

Dividends

  • Dividend Date N/A
  • ExDividend Date N/A
  • Dividend Yield 0%
View More

Catalyst Pharmaceuticals, Inc (CPRX) Dividend Calendar:

Ex-Dividend Date Payment Date Record Date Declared Date Amount

Catalyst Pharmaceuticals, Inc (CPRX) Earnings History:

Companies typically report earnings on both a quarterly and annual basis. Earnings reported that deviate from analysts' expectations can have a large impact on a stock's price.


Quarter Date Report Date Actual Revenue Reported EPS EPS Estimate Deviation from Estimate
2020-12-312021-03-16$31.01 million$0.11$0.0922.22%
2020-09-302020-11-09$N/A$0.41$0.10327.08%
2020-06-302020-08-10$N/A$0.09$0.095.88%
2020-03-312020-05-11$29.14 million$0.10$0.0915.34%
2019-12-312020-03-16$30.12 million$0.07$0.10-32.24%
2019-09-302019-11-12$30.9 million$0.13$0.1114.04%
2019-06-302019-08-07$28.84 million$0.10$0.03263.64%
2019-03-312019-05-10$12.45 million-$0.01-$0.1190.91%
2018-12-312019-03-18$500000-$0.14-$0.12-21.74%
2018-09-302018-11-07$N/A-$0.08-$0.08-6.67%
2018-06-302018-08-07$N/A-$0.06-$0.0820%
2018-03-312018-05-09$N/A-$0.06-$0.060%
2017-12-312018-03-14$N/A-$0.06-$0.060%
2017-09-302017-11-08$N/A-$0.05-$0.069.09%
2017-06-302017-08-09$N/A-$0.05-$0.0620%
2017-03-312017-05-10$N/A-$0.06-$0.060%
2016-12-312017-03-15$N/A-$0.05-$0.0725.93%
2016-09-302016-11-09$N/A-$0.05-$0.0616.67%
2016-06-302016-08-09$N/A-$0.06-$0.0820%
2016-03-312016-05-10$N/A-$0.07-$0.07-4.95%
2015-12-312016-03-15$N/A-$0.07-$0.07-3.7%
2015-09-302015-11-09$N/A-$0.05-$0.0728.57%
2015-06-302015-08-10$N/A-$0.06-$0.0714.29%
2015-03-312015-05-11$N/A-$0.07-$0.0922.22%
2014-12-312015-03-16$N/A-$0.05-$0.0728.57%
2014-09-302014-11-13$N/A-$0.07-$0.05-40%
2014-06-302014-08-13$N/A-$0.05-$0.0728.57%
2014-03-312014-05-15$N/A-$0.07-$0.06-16.67%
2013-12-312014-03-19$N/A-$0.02-$0.0771.43%
2013-09-302013-11-14$N/A-$0.13-$0.07-85.71%
2013-06-302013-08-15$N/A-$0.08-$0.06-33.33%
2013-03-312013-04-02$N/A-$0.04-$0.0955.56%
2012-09-302012-11-15$N/A-$0.08-$0.03-166.67%
2012-06-302012-08-15$N/A-$0.01-$0.0475%
2012-03-312012-04-02$N/A-$0.10-$0.06-66.67%
2011-09-302011-11-15$N/A-$0.05-$0.0728.57%
2011-06-302011-08-16$N/A-$0.06-$0.0825%
2011-03-312011-04-01$N/A-$0.04-$0.0742.86%
2010-12-312011-03-31$489000-$0.04-$0.0742.86%
2010-09-302010-11-16$N/A-$0.05-$0.0837.5%
2010-06-302010-08-13$N/A-$0.07-$0.070%
2010-03-312010-04-01$N/A-$0.06-$0.05-20%
2009-12-312010-03-31$N/A-$0.06-$0.05-20%
2009-09-302009-11-12$N/A-$0.09-$0.1010%
2009-06-302009-08-07$N/A-$0.13-$0.2035%
2009-03-312009-05-14$N/A-$0.22-$0.248.33%
2008-12-312009-03-26$N/A-$0.27-$0.23-17.39%
2008-09-302008-11-14$N/A-$0.22-$0.234.35%
2008-06-302008-08-15$N/A-$0.19
2008-03-312008-05-16$N/A-$0.13-$0.12-8.33%
2007-12-312008-03-26$N/A-$0.08-$0.07-14.29%
2007-09-302007-11-14$N/A-$0.06-$0.1662.5%
2007-06-302007-08-10$N/A-$0.10-$0.1428.57%
2007-03-312007-04-02$N/A-$0.07-$0.070%
2006-09-302006-12-16$N/A-$0.27

Catalyst Pharmaceuticals, Inc (CPRX) Company Financial Statements:

Financial statements are reports prepared by a company's management to present their financial performance and position at a point in time. A general-purpose set of financial statements usually includes a balance sheet, income statements, and statement of cash flows.

Income Statement:
Date
Research Development
Income Before Tax
Selling General Administrative
Gross Profit
Ebit
Operating Income
Income Tax Expense
Total Revenue
Cost of Revenue
Total Other Income Expense Net
Net Income From Continuing Operations
Net Income Applicable to Common Shares
Cash Flow:
Date
Investments
Change to Liabilities
Total Cash Flow from Investing Activities
Net Borrowings
Total Cash Flow from Financial Activities
Change to Operating Activities
Change in Cash
Total Cash from Operating Activities
Depreciation
Other Cash Flow from Investing Activities
Change to Inventory
Change to Account Receivables
Other Cash Flow from Financing Activities
Change to Net Income
Capital Expenditures
Balance Sheet:
Date
Total Liabailities
Total Stockholder Equity
Other Current Liabilities
Total Assets
Common Stock
Other Current Assets
Retained Earnings
Other Liabilities
Other Assets
Cash
Total Current Liabilities
Other Stockholder Equity
Property, Plant & Equipment
Total Current Assets
Long Term Investments
Net Tangible Assets
Short Term Investments
Long Term Debt
Inventory
Accounts Payable

Catalyst Pharmaceuticals, Inc (CPRX) Chart:

Catalyst Pharmaceuticals, Inc (CPRX) News:

Below you will find a list of latest news for Catalyst Pharmaceuticals, Inc (CPRX) from major news sources. You can filter the results to only show news from a specific source.

No recent news available

Catalyst Pharmaceuticals, Inc (CPRX) Options:

A stock option is a contract between two parties in which the stock option buyer (holder) purchases the right (but not the obligation) to buy/sell 100 shares of an underlying stock at a predetermined price from/to the option seller (writer) within a fixed period of time.

Expiration Date Strike Last Price Type Volume Open Interest Implied Volatility In The Money Change Change Percent
2024-05-172.50CALL0 0546.61TRUE00
2024-05-1750CALL0 0388.42TRUE00
2024-05-177.50CALL0 0261.94TRUE00
2024-05-17100CALL0 0226.2TRUE00
2024-05-1712.53.31CALL0 879.31TRUE00
2024-05-17150.85CALL7 7250.23TRUE-0.15-0.15
2024-05-1717.50.05CALL44 42338.23FALSE-0.05-0.5
2024-05-17200.11CALL0 2260FALSE00
2024-05-1722.50.02CALL0 60FALSE00
2024-05-17250CALL0 00FALSE00
2024-05-17300.38CALL0 10FALSE00
2024-05-172.50PUT0 00FALSE00
2024-05-1750PUT0 00FALSE00
2024-05-177.50PUT0 00FALSE00
2024-05-17100PUT0 00FALSE00
2024-05-1712.50.1PUT0 1030FALSE00
2024-05-17150.57PUT378 22941.66FALSE0.570
2024-05-1717.52.34PUT1 361.22TRUE2.340
2024-05-17200PUT0 093.21TRUE00
2024-05-1722.50PUT0 0146TRUE00
2024-05-17250PUT0 0153.18TRUE00
2024-05-17300PUT0 0183.08TRUE00
2024-06-212.50CALL0 0274.33TRUE00
2024-06-21510.2CALL1 152146.54TRUE-0.49-0.05
2024-06-217.56CALL0 2179.6TRUE00
2024-06-21105.4CALL0 9699.29TRUE00
2024-06-2112.52.95CALL0 31048.43TRUE00
2024-06-21151.15CALL1 30242.9TRUE-0.15-0.12
2024-06-2117.50.29CALL39 47240.58FALSE-0.17-0.37
2024-06-21200.05CALL11 37439.73FALSE-0.25-0.83
2024-06-2122.50.15CALL0 2000FALSE00
2024-06-21250.05CALL8 5463.73FALSE0.050
2024-06-21300CALL0 00FALSE00
2024-06-212.50PUT0 00FALSE00
2024-06-2150PUT0 00FALSE00
2024-06-217.50.25PUT0 10FALSE00
2024-06-21100.25PUT0 5110FALSE00
2024-06-2112.50.3PUT0 43850.94FALSE00
2024-06-21150.95PUT6 17743.85FALSE0.120.14
2024-06-2117.52.55PUT10 8538.91TRUE2.550
2024-06-21203.42PUT0 5455.62TRUE00
2024-06-2122.50PUT0 071.83TRUE00
2024-06-21250PUT0 0106.43TRUE00
2024-06-21300PUT0 0141.83TRUE00
2024-09-202.511.4CALL0 10190.6TRUE00
2024-09-20510.2CALL1 116153.55TRUE-0.5-0.05
2024-09-207.58.7CALL0 5100.69TRUE00
2024-09-20105.7CALL0 1955.42TRUE00
2024-09-2012.53.76CALL0 13346.76TRUE00
2024-09-20151.7CALL1 15042.82TRUE-0.25-0.13
2024-09-2017.50.85CALL3 29140.63FALSE0.850
2024-09-20200.55CALL1 10340.6FALSE00
2024-09-2022.50.25CALL0 2162.55FALSE00
2024-09-20250.13CALL0 3680FALSE00
2024-09-20300.05CALL0 100FALSE00
2024-09-202.50PUT0 00FALSE00
2024-09-2050PUT0 00FALSE00
2024-09-207.50PUT0 00FALSE00
2024-09-20100.25PUT0 651.34FALSE00
2024-09-2012.50.46PUT0 2644.63FALSE00
2024-09-20151.2PUT0 1142.91FALSE00
2024-09-2017.52.65PUT0 10740.84TRUE00
2024-09-20204.8PUT0 148.55TRUE00
2024-09-2022.50PUT0 058.64TRUE00
2024-09-20250PUT0 077.02TRUE00
2024-09-20300PUT0 080.2TRUE00
2024-12-202.50CALL0 0163.42TRUE00
2024-12-20510.3CALL10 1065.44TRUE-0.5-0.05
2024-12-207.50CALL0 067.85TRUE00
2024-12-20100CALL0 031.57TRUE00
2024-12-2012.50CALL0 060TRUE00
2024-12-20152.3CALL1 041.34TRUE2.30
2024-12-2017.51.2CALL1 138.11FALSE-0.5-0.29
2024-12-20200CALL0 041.43FALSE00
2024-12-2022.50CALL0 044.92FALSE00
2024-12-20250CALL0 042.99FALSE00
2024-12-20300CALL0 00FALSE00
2024-12-202.50PUT0 00FALSE00
2024-12-2050PUT0 00FALSE00
2024-12-207.50PUT0 00FALSE00
2024-12-20100PUT0 065FALSE00
2024-12-2012.50PUT0 045.01FALSE00
2024-12-20150PUT0 042.92FALSE00
2024-12-2017.50PUT0 040.03TRUE00
2024-12-20200PUT0 046.66TRUE00
2024-12-2022.50PUT0 046.33TRUE00
2024-12-20250PUT0 0103.22TRUE00
2024-12-20300PUT0 074.34TRUE00

Latest CPRX Trades:

Date Shares Price
Jun 13, 2022 7:59 PM EST2$6.24
Jun 13, 2022 7:59 PM EST100$6.24
Jun 13, 2022 7:59 PM EST86$6.24
Jun 13, 2022 7:59 PM EST100$6.24
Jun 13, 2022 7:59 PM EST37$6.235

Catalyst Pharmaceuticals, Inc (CPRX) SEC Filings:

An SEC filing is a financial statement or other formal document submitted to the U.S. Securities and Exchange Commission (SEC). Public companies, certain insiders, and broker-dealers are required to make regular SEC filings.

Date Form Type Form Name Link
2020-07-023Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1369568/000116169720000294/0001161697-20-000294-index.htm
2019-11-08UPLOADSEC-generated letterhttps://www.sec.gov/Archives/edgar/data/1369568/000000000019015379/0000000000-19-015379-index.htm
2019-12-13UPLOADSEC-generated letterhttps://www.sec.gov/Archives/edgar/data/1369568/000000000019016411/0000000000-19-016411-index.htm
2020-07-30UPLOADSEC-generated letterhttps://www.sec.gov/Archives/edgar/data/1369568/000000000020006980/0000000000-20-006980-index.htm
2020-02-14SC 13GStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1369568/000009375120000600/0000093751-20-000600-index.htm
2019-02-08SC 13GStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1369568/000021545719006748/0000215457-19-006748-index.htm
2020-02-05SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1369568/000083423720004631/0000834237-20-004631-index.htm
2018-06-153Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1369568/000089924318016787/0000899243-18-016787-index.htm
2018-02-13SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1369568/000091957418001185/0000919574-18-001185-index.htm
2019-02-13SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1369568/000091957419001193/0000919574-19-001193-index.htm
2020-02-13SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1369568/000091957420001116/0000919574-20-001116-index.htm
2020-02-13SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1369568/000091957420001126/0000919574-20-001126-index.htm
2020-03-26SC 13GStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1369568/000091957420002583/0000919574-20-002583-index.htm
2018-02-14SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1369568/000093041318000494/0000930413-18-000494-index.htm
2019-02-14SC 13GStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1369568/000108514619000736/0001085146-19-000736-index.htm
2019-03-06SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1369568/000108514619001021/0001085146-19-001021-index.htm
2019-12-09SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1369568/000108514619003054/0001085146-19-003054-index.htm
2020-01-09SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1369568/000108514620000053/0001085146-20-000053-index.htm
2018-02-13SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1369568/000114420418007914/0001144204-18-007914-index.htm
2019-02-13SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1369568/000114420419007221/0001144204-19-007221-index.htm
2018-01-044Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1369568/000116169718000030/0001161697-18-000030-index.htm
2018-01-044Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1369568/000116169718000032/0001161697-18-000032-index.htm
2018-01-044Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1369568/000116169718000034/0001161697-18-000034-index.htm
2018-01-044Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1369568/000116169718000036/0001161697-18-000036-index.htm
2018-01-044Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1369568/000116169718000038/0001161697-18-000038-index.htm
2018-04-034Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1369568/000116169718000180/0001161697-18-000180-index.htm
2018-05-314Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1369568/000116169718000296/0001161697-18-000296-index.htm
2018-05-314Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1369568/000116169718000300/0001161697-18-000300-index.htm
2018-06-014Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1369568/000116169718000302/0001161697-18-000302-index.htm
2018-06-074Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1369568/000116169718000306/0001161697-18-000306-index.htm
2018-06-084Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1369568/000116169718000308/0001161697-18-000308-index.htm
2018-06-114Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1369568/000116169718000312/0001161697-18-000312-index.htm
2018-12-144Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1369568/000116169718000579/0001161697-18-000579-index.htm
2018-12-174Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1369568/000116169718000583/0001161697-18-000583-index.htm
2018-12-194Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1369568/000116169718000599/0001161697-18-000599-index.htm
2018-12-214Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1369568/000116169718000618/0001161697-18-000618-index.htm
2018-12-214Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1369568/000116169718000619/0001161697-18-000619-index.htm
2018-12-214Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1369568/000116169718000620/0001161697-18-000620-index.htm
2018-12-214Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1369568/000116169718000621/0001161697-18-000621-index.htm
2018-12-214Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1369568/000116169718000622/0001161697-18-000622-index.htm
2018-12-214Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1369568/000116169718000623/0001161697-18-000623-index.htm
2018-12-214Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1369568/000116169718000624/0001161697-18-000624-index.htm
2018-12-214Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1369568/000116169718000625/0001161697-18-000625-index.htm
2018-12-214Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1369568/000116169718000626/0001161697-18-000626-index.htm
2018-12-214Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1369568/000116169718000627/0001161697-18-000627-index.htm
2018-12-284Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1369568/000116169718000634/0001161697-18-000634-index.htm
2019-01-043Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1369568/000116169719000018/0001161697-19-000018-index.htm
2019-06-114Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1369568/000116169719000233/0001161697-19-000233-index.htm
2019-10-034Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1369568/000116169719000421/0001161697-19-000421-index.htm
2019-10-114Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1369568/000116169719000434/0001161697-19-000434-index.htm
2019-11-224Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1369568/000116169719000503/0001161697-19-000503-index.htm
2019-11-274Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1369568/000116169719000508/0001161697-19-000508-index.htm
2019-12-044Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1369568/000116169719000510/0001161697-19-000510-index.htm
2019-12-044Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1369568/000116169719000512/0001161697-19-000512-index.htm
2019-12-044Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1369568/000116169719000514/0001161697-19-000514-index.htm
2019-12-044Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1369568/000116169719000516/0001161697-19-000516-index.htm
2019-12-044Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1369568/000116169719000518/0001161697-19-000518-index.htm
2019-12-044Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1369568/000116169719000520/0001161697-19-000520-index.htm
2019-12-044Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1369568/000116169719000522/0001161697-19-000522-index.htm
2019-12-044Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1369568/000116169719000524/0001161697-19-000524-index.htm
2019-12-044Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1369568/000116169719000526/0001161697-19-000526-index.htm
2019-12-044Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1369568/000116169719000528/0001161697-19-000528-index.htm
2019-12-044Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1369568/000116169719000530/0001161697-19-000530-index.htm
2019-12-064Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1369568/000116169719000538/0001161697-19-000538-index.htm
2020-07-023Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1369568/000116169720000294/0001161697-20-000294-index.htm
2020-09-304Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1369568/000116169720000416/0001161697-20-000416-index.htm
2020-09-304Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1369568/000116169720000418/0001161697-20-000418-index.htm
2018-01-088-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1369568/000119312518005402/0001193125-18-005402-index.htm
2018-02-128-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1369568/000119312518039004/0001193125-18-039004-index.htm
2018-03-1410-KAnnual report [Section 13 and 15(d), not S-K Item 405]https://www.sec.gov/Archives/edgar/data/1369568/000119312518082292/0001193125-18-082292-index.htm
2018-03-148-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1369568/000119312518082373/0001193125-18-082373-index.htm
2018-03-298-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1369568/000119312518100672/0001193125-18-100672-index.htm
2018-04-17DEF 14AOther definitive proxy statementshttps://www.sec.gov/Archives/edgar/data/1369568/000119312518119932/0001193125-18-119932-index.htm
2018-04-198-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1369568/000119312518121919/0001193125-18-121919-index.htm
2018-05-0910-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1369568/000119312518157513/0001193125-18-157513-index.htm
2018-05-098-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1369568/000119312518157634/0001193125-18-157634-index.htm
2018-05-258-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1369568/000119312518175523/0001193125-18-175523-index.htm
2018-05-298-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1369568/000119312518176046/0001193125-18-176046-index.htm
2018-05-318-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1369568/000119312518180466/0001193125-18-180466-index.htm
2018-06-158-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1369568/000119312518194622/0001193125-18-194622-index.htm
2018-06-29S-8Securities to be offered to employees in employee benefit planshttps://www.sec.gov/Archives/edgar/data/1369568/000119312518209752/0001193125-18-209752-index.htm
2018-08-0710-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1369568/000119312518241075/0001193125-18-241075-index.htm
2018-08-078-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1369568/000119312518241295/0001193125-18-241295-index.htm
2018-08-178-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1369568/000119312518251807/0001193125-18-251807-index.htm
2018-11-0710-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1369568/000119312518320889/0001193125-18-320889-index.htm
2018-11-078-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1369568/000119312518320996/0001193125-18-320996-index.htm
2018-11-298-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1369568/000119312518337245/0001193125-18-337245-index.htm
2018-12-178-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1369568/000119312518350053/0001193125-18-350053-index.htm
2018-12-188-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1369568/000119312518352167/0001193125-18-352167-index.htm
2018-12-268-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1369568/000119312518358175/0001193125-18-358175-index.htm
2019-03-1810-KAnnual report [Section 13 and 15(d), not S-K Item 405]https://www.sec.gov/Archives/edgar/data/1369568/000119312519078253/0001193125-19-078253-index.htm
2019-03-188-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1369568/000119312519078324/0001193125-19-078324-index.htm
2019-04-18DEF 14AOther definitive proxy statementshttps://www.sec.gov/Archives/edgar/data/1369568/000119312519111052/0001193125-19-111052-index.htm
2019-05-1010-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1369568/000119312519144387/0001193125-19-144387-index.htm
2019-05-138-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1369568/000119312519144832/0001193125-19-144832-index.htm
2019-05-248-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1369568/000119312519157023/0001193125-19-157023-index.htm
2019-05-298-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1369568/000119312519159724/0001193125-19-159724-index.htm
2019-05-308-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1369568/000119312519161413/0001193125-19-161413-index.htm
2019-06-128-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1369568/000119312519171385/0001193125-19-171385-index.htm
2019-08-0710-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1369568/000119312519215324/0001193125-19-215324-index.htm
2019-08-078-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1369568/000119312519215383/0001193125-19-215383-index.htm
2019-08-308-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1369568/000119312519235335/0001193125-19-235335-index.htm
2019-09-11424B5Prospectus [Rule 424(b)(5)]https://www.sec.gov/Archives/edgar/data/1369568/000119312519243060/0001193125-19-243060-index.htm
2019-09-138-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1369568/000119312519244473/0001193125-19-244473-index.htm
2019-09-248-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1369568/000119312519253620/0001193125-19-253620-index.htm
2019-10-308-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1369568/000119312519278423/0001193125-19-278423-index.htm
2019-11-1210-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1369568/000119312519290006/0001193125-19-290006-index.htm
2019-11-128-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1369568/000119312519290047/0001193125-19-290047-index.htm
2019-11-12CORRESPCorrespondencehttps://www.sec.gov/Archives/edgar/data/1369568/000119312519290068/0001193125-19-290068-index.htm
2019-11-278-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1369568/000119312519302591/0001193125-19-302591-index.htm
2019-12-06CORRESPCorrespondencehttps://www.sec.gov/Archives/edgar/data/1369568/000119312519308282/0001193125-19-308282-index.htm
2020-01-068-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1369568/000119312520001827/0001193125-20-001827-index.htm
2020-02-058-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1369568/000119312520024885/0001193125-20-024885-index.htm
2020-03-1610-KAnnual report [Section 13 and 15(d), not S-K Item 405]https://www.sec.gov/Archives/edgar/data/1369568/000119312520075048/0001193125-20-075048-index.htm
2020-03-178-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1369568/000119312520075118/0001193125-20-075118-index.htm
2020-04-088-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1369568/000119312520100911/0001193125-20-100911-index.htm
2020-04-2910-K/AAnnual report [Section 13 and 15(d), not S-K Item 405]https://www.sec.gov/Archives/edgar/data/1369568/000119312520126361/0001193125-20-126361-index.htm
2020-05-1110-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1369568/000119312520139026/0001193125-20-139026-index.htm
2020-05-118-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1369568/000119312520139277/0001193125-20-139277-index.htm
2020-05-138-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1369568/000119312520141636/0001193125-20-141636-index.htm
2020-06-18PRE 14AOther preliminary proxy statementshttps://www.sec.gov/Archives/edgar/data/1369568/000119312520172628/0001193125-20-172628-index.htm
2020-06-268-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1369568/000119312520180912/0001193125-20-180912-index.htm
2020-07-07DEF 14AOther definitive proxy statementshttps://www.sec.gov/Archives/edgar/data/1369568/000119312520188818/0001193125-20-188818-index.htm
2020-07-23S-3Registration statement under Securities Act of 1933https://www.sec.gov/Archives/edgar/data/1369568/000119312520197849/0001193125-20-197849-index.htm
2020-07-30CORRESPCorrespondencehttps://www.sec.gov/Archives/edgar/data/1369568/000119312520203849/0001193125-20-203849-index.htm
2020-07-31424B3Prospectus [Rule 424(b)(3)]https://www.sec.gov/Archives/edgar/data/1369568/000119312520206659/0001193125-20-206659-index.htm
2020-08-03DEFA14AAdditional definitive proxy soliciting materials and Rule 14(a)(12) materialhttps://www.sec.gov/Archives/edgar/data/1369568/000119312520208176/0001193125-20-208176-index.htm
2020-08-038-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1369568/000119312520208186/0001193125-20-208186-index.htm
2020-08-068-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1369568/000119312520211962/0001193125-20-211962-index.htm
2020-08-1010-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1369568/000119312520214907/0001193125-20-214907-index.htm
2020-08-108-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1369568/000119312520215047/0001193125-20-215047-index.htm
2020-08-118-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1369568/000119312520216413/0001193125-20-216413-index.htm
2020-08-208-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1369568/000119312520225731/0001193125-20-225731-index.htm
2020-08-218-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1369568/000119312520227098/0001193125-20-227098-index.htm
2020-08-268-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1369568/000119312520231392/0001193125-20-231392-index.htm
2020-09-118-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1369568/000119312520244230/0001193125-20-244230-index.htm
2020-09-308-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1369568/000119312520258125/0001193125-20-258125-index.htm
2020-10-068-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1369568/000119312520264855/0001193125-20-264855-index.htm
2020-10-198-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1369568/000119312520271679/0001193125-20-271679-index.htm
2020-07-31EFFECTNotice of Effectivenesshttps://www.sec.gov/Archives/edgar/data/1369568/999999999520001997/9999999995-20-001997-index.htm
2018-09-28CT ORDERConfidential treatment orderhttps://www.sec.gov/Archives/edgar/data/1369568/999999999718008220/9999999997-18-008220-index.htm
2019-02-27CT ORDERConfidential treatment orderhttps://www.sec.gov/Archives/edgar/data/1369568/999999999719000606/9999999997-19-000606-index.htm

Catalyst Pharmaceuticals, Inc (CPRX) Insider Transactions:

Here you will find a list of insider trading activities (stock purchases, sales, and option exercises) reported by insiders of Catalyst Pharmaceuticals, Inc (CPRX). Company insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise.
Insider Ownership: 698%
Institutional Ownership: 6958%

Transaction Date Insider Name Insider Title Type Shares Number Shares Price Total Transaction Shares Held After Transaction Link
2019-11-21GARY INGENITOChief Medical OfficerSell100,000.004.50449,800.000.00https://www.sec.gov/Archives/edgar/data/1369568/000116169719000503/0001161697-19-000503-index.htm
2019-11-27GARY INGENITOChief Medical OfficerSell100,000.004.66466,000.000.00https://www.sec.gov/Archives/edgar/data/1369568/000116169719000508/0001161697-19-000508-index.htm
2019-12-05GARY INGENITOChief Medical OfficerSell150,000.004.82723,150.000.00https://www.sec.gov/Archives/edgar/data/1369568/000116169719000538/0001161697-19-000538-index.htm
2019-11-20GARY INGENITOChief Medical OfficerBuy100,000.000.7979,000.00100,000.00https://www.sec.gov/Archives/edgar/data/1369568/000116169719000503/0001161697-19-000503-index.htm
2019-11-27GARY INGENITOChief Medical OfficerBuy100,000.001.13113,000.00100,000.00https://www.sec.gov/Archives/edgar/data/1369568/000116169719000508/0001161697-19-000508-index.htm
2018-05-30DONALD A DENKHAUSDirectorBuy20,000.003.7575,000.00120,000.00https://www.sec.gov/Archives/edgar/data/1369568/000116169718000296/0001161697-18-000296-index.htm
2018-06-08DONALD A DENKHAUSDirectorBuy20,000.003.4168,200.00140,000.00https://www.sec.gov/Archives/edgar/data/1369568/000116169718000312/0001161697-18-000312-index.htm
2019-12-04GARY INGENITOChief Medical OfficerBuy150,000.002.53379,500.00150,000.00https://www.sec.gov/Archives/edgar/data/1369568/000116169719000538/0001161697-19-000538-index.htm
2018-12-14DONALD A DENKHAUSDirectorBuy60,000.002.48148,800.00200,000.00https://www.sec.gov/Archives/edgar/data/1369568/000116169718000583/0001161697-18-000583-index.htm
2018-12-27DONALD A DENKHAUSDirectorBuy25,000.001.9147,750.00225,000.00https://www.sec.gov/Archives/edgar/data/1369568/000116169718000634/0001161697-18-000634-index.htm
2018-04-03PATRICK J MCENANYPresident and CEOBuy20,000.002.2945,800.004,717,693.00https://www.sec.gov/Archives/edgar/data/1369568/000116169718000180/0001161697-18-000180-index.htm
2018-12-19PATRICK J MCENANYPresident and CEOBuy20,000.002.2444,800.004,737,693.00https://www.sec.gov/Archives/edgar/data/1369568/000116169718000599/0001161697-18-000599-index.htm
2019-06-11PATRICK J MCENANYPresident and CEOBuy25,000.003.2380,750.004,762,693.00https://www.sec.gov/Archives/edgar/data/1369568/000116169719000233/0001161697-19-000233-index.htm
2019-10-03PATRICK J MCENANYPresident and CEOBuy10,000.004.8948,900.004,772,693.00https://www.sec.gov/Archives/edgar/data/1369568/000116169719000421/0001161697-19-000421-index.htm
2020-09-30PATRICK J MCENANYPresident and CEOBuy15,000.002.9744,550.004,787,693.00https://www.sec.gov/Archives/edgar/data/1369568/000116169720000416/0001161697-20-000416-index.htm
2018-06-01Charles B O'KeeffeDirectorBuy5,000.003.7418,680.00518,376.00https://www.sec.gov/Archives/edgar/data/1369568/000116169718000302/0001161697-18-000302-index.htm
2018-06-07Charles B O'KeeffeDirectorBuy4,000.003.3113,222.00522,376.00https://www.sec.gov/Archives/edgar/data/1369568/000116169718000306/0001161697-18-000306-index.htm
2018-06-07Charles B O'KeeffeDirectorBuy1,000.003.353,352.30523,376.00https://www.sec.gov/Archives/edgar/data/1369568/000116169718000308/0001161697-18-000308-index.htm
2018-12-14Charles B O'KeeffeDirectorBuy20,000.002.5050,000.00543,376.00https://www.sec.gov/Archives/edgar/data/1369568/000116169718000579/0001161697-18-000579-index.htm
2019-10-11Charles B O'KeeffeDirectorBuy10,000.004.7046,950.00553,376.00https://www.sec.gov/Archives/edgar/data/1369568/000116169719000434/0001161697-19-000434-index.htm
2020-09-30Charles B O'KeeffeDirectorBuy7,000.002.9920,930.00560,376.00https://www.sec.gov/Archives/edgar/data/1369568/000116169720000418/0001161697-20-000418-index.htm